Literature DB >> 28756021

Association of clinical severity of cystic fibrosis with variants in the SLC gene family (SLC6A14, SLC26A9, SLC11A1 and SLC9A3).

Stéphanie Villa-Nova Pereira1, José Dirceu Ribeiro2, Carmen Sílvia Bertuzzo3, Fernando Augusto Lima Marson4.   

Abstract

INTRODUCTION: Cystic fibrosis (CF) manifests with clinical and histopathological variability depending on environmental and genetic factors. Moreover, the genes encoding ion channels[rs3788766(SLC6A14), rs7512462(SLC26A9), rs17235416(SLC11A1) and rs17563161(SLC9A3)] have been insufficiently studied as modifier genes. Then, our objective was associate the variants in the genes of SLC family with 43 CF severity markers.
METHODS: The variants were identified by real-time-PCR in 188 CF patients considering the CFTR genotype. Statistical analyses were performed by parametric and nonparametric tests. The correction by multiple testing was performed by the False Rate Discovery test, alpha=0.05.
RESULTS: Depending on the CFTR mutations, we found association of: (i) rs3788766*CC with mucoid Pseudomonas aeruginosa (OR=0.171; 95%CI=0.029-0.696), non-mucoid P. aeruginosa (OR=0.283; 95%CI=0.094-0.853) and Staphyloccocus aureus (OR=4.443; 95%CI=1.019-40.64), largest FEFmax(p=0.041) and best response to bronchodilator for FEF50%(p=0.033) and FEV1/FVC(p=0.044); (ii) rs3788766*CT with early start of pulmonary symptom (OR=3.524; 95%CI=1.229-10.1) and osteoporosis (OR=0.203; 95%CI=0.022-0.883); (iii) rs3788766*TT with lowest body mass index (OR=4.242; 95%CI=1.505-11.95), presence of mucoid P. aeruginosa (OR=3.176; 95%CI=1.29-7.819) and S. aureus (OR=0.116; 95%CI=0.004-0.881), highest Bhalla score (p=0.047) and lowest FEFmax(p=0.028) and FEF25%(p=0.031) values; (iv) rs7512462*CC with highest Shwachman-Kulczycki score (p=0.019), FVC(p=0.043), FEV1(p=0.047), FEV1/FVC(p=0.022), FEF50%(p=0.038) and FEF25-75%(p=0.016); (v) rs7512462*CT with lowest values of FVC(p=0.034), FEV1(p=0.047), FEV1/FVC(p=0.022), FEF25%(p=0.012), FEF50%(p=0.038), FEF75%(p=0.008), FEF25-75%(p=0.016) and ERV(p=0.023); (vi) rs7512462*TT with best response to the inhaled bronchodilator for FEV1(p=0.011), FEF50%(p=0.019), FEF75%(p=0.036) and FEF25-75%(p=0.008); (vii) rs17234516*Normal allele with lowest value of SaO2 (p=0.010) and S. aureus (OR=3.333; 95%CI=1.085-10.24); (viii) rs17563161*GG with lowest age for onset of digestive symptoms (OR=2.564; 95%CI=1.234-5.33).
CONCLUSIONS: The clinical and laboratory variability of CF were associated with the variants in the genes of SLC family in our sample.
Copyright © 2017 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  CFTR; Variability; rs17235416; rs17563161; rs3788766; rs7512462

Mesh:

Substances:

Year:  2017        PMID: 28756021     DOI: 10.1016/j.gene.2017.07.068

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  15 in total

Review 1.  The Na+/Cl--Coupled, Broad-Specific, Amino Acid Transporter SLC6A14 (ATB0,+): Emerging Roles in Multiple Diseases and Therapeutic Potential for Treatment and Diagnosis.

Authors:  Mohd Omar F Sikder; Shengping Yang; Vadivel Ganapathy; Yangzom D Bhutia
Journal:  AAPS J       Date:  2017-12-04       Impact factor: 4.009

2.  Na+/H+ Exchangers Are Required for the Development and Function of Vertebrate Mucociliary Epithelia.

Authors:  Dingyuan I Sun; Alexia Tasca; Maximilian Haas; Grober Baltazar; Richard M Harland; Walter E Finkbeiner; Peter Walentek
Journal:  Cells Tissues Organs       Date:  2018-10-09       Impact factor: 2.481

Review 3.  [Cystic fibrosis being a polyendocrine disease (Review)].

Authors:  N B Chagay; G Ya Khayt; T M Vdovina; A A Shaforost
Journal:  Probl Endokrinol (Mosk)       Date:  2021-03-30

Review 4.  Physiological and Pathophysiological Relevance of the Anion Transporter Slc26a9 in Multiple Organs.

Authors:  Xuemei Liu; Taolang Li; Biguang Tuo
Journal:  Front Physiol       Date:  2018-08-28       Impact factor: 4.566

Review 5.  Role of the SLC26A9 Chloride Channel as Disease Modifier and Potential Therapeutic Target in Cystic Fibrosis.

Authors:  Anita Balázs; Marcus A Mall
Journal:  Front Pharmacol       Date:  2018-10-01       Impact factor: 5.810

6.  SLC9A3 Affects Vas Deferens Development and Associates with Taiwanese Congenital Bilateral Absence of the Vas Deferens.

Authors:  Yi-No Wu; Kuo-Chiang Chen; Chien-Chih Wu; Ying-Hung Lin; Han-Sun Chiang
Journal:  Biomed Res Int       Date:  2019-03-10       Impact factor: 3.411

7.  Pancreatitis: TIGAR-O Version 2 Risk/Etiology Checklist With Topic Reviews, Updates, and Use Primers.

Authors:  David C Whitcomb
Journal:  Clin Transl Gastroenterol       Date:  2019-06       Impact factor: 4.488

Review 8.  The impact of host genetic background in the Pseudomonas aeruginosa respiratory infections.

Authors:  Nicola Ivan Loré; Cristina Cigana; Barbara Sipione; Alessandra Bragonzi
Journal:  Mamm Genome       Date:  2018-06-12       Impact factor: 2.957

9.  SLC26A9 SNP rs7512462 is not associated with lung disease severity or lung function response to ivacaftor in cystic fibrosis patients with G551D-CFTR.

Authors:  Alice C Eastman; Rhonda G Pace; Hong Dang; Melis Atalar Aksit; Briana Vecchio-Pagán; Anh-Thu N Lam; Wanda K O'Neal; Scott M Blackman; Michael R Knowles; Garry R Cutting
Journal:  J Cyst Fibros       Date:  2021-03-02       Impact factor: 5.527

10.  SLC26A9 Gene Is Associated With Lung Function Response to Ivacaftor in Patients With Cystic Fibrosis.

Authors:  Harriet Corvol; Julie Mésinèle; Isman-Hassan Douksieh; Lisa J Strug; Pierre-Yves Boëlle; Loïc Guillot
Journal:  Front Pharmacol       Date:  2018-07-26       Impact factor: 5.810

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.